Mark Esq - Oncology Institute General Counsel
| TOIIW Stock | USD 0.02 0 26.85% |
Executive
Mark Esq is General Counsel of The Oncology Institute
| Address | 18000 Studebaker Road, Cerritos, CA, United States, 90703 |
| Phone | 562 735 3226 |
| Web | https://theoncologyinstitute.com |
Oncology Institute Management Efficiency
The company has return on total asset (ROA) of (0.1942) % which means that it has lost $0.1942 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.2559) %, meaning that it generated substantial loss on money invested by shareholders. Oncology Institute's management efficiency ratios could be used to measure how well Oncology Institute manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.47 in 2024. Return On Capital Employed is likely to drop to -0.46 in 2024. At this time, Oncology Institute's Non Current Assets Total are fairly stable compared to the past year. Debt To Assets is likely to climb to 0.44 in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 323.5 K in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Marissa Brittenham | Surgery Partners | 39 | |
| Andrew Lynch | Acadia Healthcare | N/A | |
| Benjamin Adams | InnovAge Holding Corp | 60 | |
| Shelly Eckenroth | Select Medical Holdings | N/A | |
| Danielle Burkhalter | Surgery Partners | 39 | |
| MS DO | Encompass Health Corp | 64 | |
| Varun Gadhok | Surgery Partners | N/A | |
| Gretchen Hommrich | Acadia Healthcare | N/A | |
| Isa Diaz | Acadia Healthcare | N/A | |
| Laura Groschen | Acadia Healthcare | N/A | |
| Mary Lacey | Select Medical Holdings | N/A | |
| Chad JD | The Ensign Group | 46 | |
| Lynette CPA | Pennant Group | 46 | |
| Kristi Jensen | Surgery Partners | N/A | |
| Roxanne Womack | Surgery Partners | N/A | |
| Bill Priest | Acadia Healthcare | N/A | |
| Christine Bent | InnovAge Holding Corp | 54 | |
| Matt Huray | InnovAge Holding Corp | N/A | |
| Patrick Esq | Healthcare Services Group | 49 | |
| Brian Rusignuolo | Select Medical Holdings | 48 | |
| Mark Palmenter | Acadia Healthcare | N/A | |
Management Performance
| Return On Equity | -1.26 | ||||
| Return On Asset | -0.19 |
The Oncology Institute Leadership Team
Elected by the shareholders, the Oncology Institute's board of directors comprises two types of representatives: Oncology Institute inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oncology. The board's role is to monitor Oncology Institute's management team and ensure that shareholders' interests are well served. Oncology Institute's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oncology Institute's outside directors are responsible for providing unbiased perspectives on the board's policies.
| FACHE MD, Chief Officer | ||
| Mark Esq, General Counsel | ||
| Rob Carter, Senior Finance | ||
| Rakesh MBA, Director Technology | ||
| Laura Szitar, Chief Officer | ||
| Richard Barasch, Executive Board | ||
| Jeremy MBA, Chief Officer | ||
| MBA JD, Senior Compliance | ||
| FACHE MBA, CEO Director | ||
| Julie Korinke, Director Communications | ||
| Mihir CPA, Chief Officer | ||
| Hilda MBA, Founder Officer | ||
| Jordan McInerney, Chief Officer | ||
| Richy MD, Founder Officer | ||
| FACS MD, Chief Practice |
Oncology Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oncology Institute a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.26 | ||||
| Return On Asset | -0.19 | ||||
| Profit Margin | (0.20) % | ||||
| Operating Margin | (0.17) % | ||||
| Number Of Shares Shorted | 4.66 K | ||||
| Revenue | 324.24 M | ||||
| EBITDA | (70.45 M) | ||||
| Net Income | (83.07 M) | ||||
| Cash And Equivalents | 15.17 M | ||||
| Total Debt | 119.67 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Oncology Stock Analysis
When running Oncology Institute's price analysis, check to measure Oncology Institute's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncology Institute is operating at the current time. Most of Oncology Institute's value examination focuses on studying past and present price action to predict the probability of Oncology Institute's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncology Institute's price. Additionally, you may evaluate how the addition of Oncology Institute to your portfolios can decrease your overall portfolio volatility.